Tuphan Kanti Dolai

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 310 citations · Full text

Hematological Malignancy, Once-per-week Selinexor, Medicine +7

Photocatalytic and antibacterial activity of cadmium sulphide/zinc oxide nanocomposite with varied morphology

Tushar K. Jana, Sanjoy Kumar Maji, Arnab Pal et al. · Journal of Colloid and Interface Science · 2016 · 86 citations

Materials Science, Varied Morphology, Engineering +9

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

Shambavi Richard, Ajai Chari, Sosana Delimpasi et al. · American Journal of Hematology · 2021 · 29 citations · Full text

Boston Study, Dexamethasone Versus Bortezomib, Pathology +17

Prevalance of Iron Deficiency in Thalassemia Minor: A Study from Tertiary Hospital

Tuphan Kanti Dolai, K.S. Nataraj, Nidhi Sinha et al. · Indian Journal of Hematology and Blood Transfusion · 2011 · 28 citations · Full text

Anemia, Pediatric Hematology, Hematology +5

Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.

Meletios Α. Dimopoulos, Sosana Delimpasi, Maryana Simonova et al. · Journal of Clinical Oncology · 2020 · 25 citations

Cancer Management, Prior Therapies, Pathology +22